lung cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and pancreatic cancer (Table 2) . [20] [21] [22] [23] [24] (For relevant clinical studies supporting the use of anti-EGFR drugs in the first three conditions, see Tables 1, 2 , and 3 in the Supplementary Appendix, available with the full text of this article at www.nejm.org.)
Non-Small-Cell Lung Cancer
Phase 1 trials showed that gefitinib and erlotinib have important clinical activity in patients with Bind intracellular portion of receptor within tyrosine kinase domain, generally by competing with ATP and inhibiting receptor autophosphorylation; most are reversible; irreversible EGFR tyrosine kinase inhibitors are in clinical development
Cellular effects of EGFR inhibition
Inhibit cancer-cell proliferation (G1 phase arrest), angiogenic growth factor production (VEGF) and tumor-induced angiogenesis, and cancercell invasion; potentiate antitumor activity of cytotoxic drugs and radiotherapy
Inhibit cancer-cell proliferation (G0-G1 phase arrest), angiogenic growth factor production (VEGF) and tumor-induced angiogenesis, and cancer-cell invasion; potentiate antitumor activity of cytotoxic drugs and radiotherapy 19 and L858R in exon 21), since these EGFR mutant proteins bind with higher-affinity small-molecule EGFR tyrosine kinase inhibitors, such as erlotinib or gefitinib; no, for gefitinib-or erlotinib-acquired EGFRresistance mutation (T790M in exon 20), although several new-generation EGFR tyrosine kinase inhibitors that are active against mutant EGFR proteins are in early clinical development metastatic, chemorefractory non-small-cell lung cancer. [25] [26] [27] [28] [29] Dose-dependent and reversible diarrhea and acneiform rashes have been the most prominent side effects (maximum tolerated dose, 750 mg per day for gefitinib and 150 mg per day for erlotinib). The histologic characteristics of the rash (a neutrophilic infiltrate in perifollicular areas within the basal layer of the skin) differ from those seen in typical acne and are common to all EGFR-targeted drugs, including anti-EGFR monoclonal antibodies. 30 Skin toxicity is generally observed within 2 to 3 weeks after the start of treatment and gradually resolves in most patients, even when anti-EGFR treatment is continued. The maximum tolerated dose of erlotinib (150 mg per day), based on side effects, was chosen for further study, whereas for gefitinib, relatively low doses (patients were randomly assigned to receive 250 mg or 500 mg per day), given the maximum tolerated doses, were chosen. Gefitinib was the first anti-EGFR agent that was shown, in two randomized phase 2 studies, to have clinically important antitumor activity in patients with non-small-cell lung cancer who had not had a response to one or more chemotherapy regimens, including platinum-based and docetaxel-based therapies. [30] [31] [32] The two doses of gefitinib (250 mg and 500 mg) had similar antitumor activity, but toxicity was greater at the higher dose. Therefore, the lower dose was selected for further clinical studies. These trials led the Food and Drug Administration (FDA) in May 2003 to approve gefitinib as third-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer after failure of both platinum-based and docetaxel-based chemotherapies.
However, a placebo-controlled, randomized phase 3 trial (the Iressa Survival Evaluation in Lung Cancer [ISEL] trial) failed to show that gefitinib was effective in improving survival. 33 Neither median survival nor the rate of survival at 1 year differed significantly between patients receiving gefitinib and those receiving placebo in either the overall study population or a subgroup with a history of adenocarcinoma. Pre- Erlotinib has been approved by several regulatory agencies worldwide, including the FDA and the EMEA in the European Union, as monotherapy for the treatment of non-small-cell lung cancer that is refractory to platinum-based chemotherapy. More recently, erlotinib has been approved by the FDA and the EMEA for use in combination with gemcitabine as first-line treatment for advanced pancreatic cancer.
Gefitinib
Reversible EGFR tyrosine kinase inhibitor (quinazoline-derivative molecule)
Gefitinib has been approved in various countries for use as third-line treatment of non-small-cell lung cancer that is refractory to platinum-based and docetaxelbased chemotherapy regimens. After an accelerated approval process, it was approved by the FDA in May 2003 but has been withheld from the U.S. market since June 2005, as a result of the release of preliminary results of the ISEL trial, which assessed its use in patients with non-small-cell lung cancer that was refractory to previous platinum-based chemotherapy. Gefitinib has never been approved in the European Union but is currently on the market in Japan, Korea, China, and several other Asian countries. It is currently an investigational drug in the United States and the European Union.
Cetuximab Human-mouse chimeric monoclonal antibody (IgG1 subtype)
Cetuximab has been approved by several regulatory agencies worldwide, including the FDA and the EMEA, for the treatment of advanced colorectal cancer that is refractory to irinotecan-based chemotherapy (alone or in combination with irinotecan in the United States but only in combination with irinotecan in the European Union). Cetuximab in combination with radiotherapy is also approved for the treatment of locally advanced squamous-cell carcinoma of the head and neck.
Panitumumab Fully human monoclonal antibody (IgG2κ subtype)
Panitumumab has been approved by several regulatory agencies worldwide, including the FDA, as monotherapy for third-line treatment of colorectal cancer that is refractory to fluoropyrimidines, oxaliplatin, or irinotecan. In December 2007, panitumumab was approved by the EMEA for use in patients with colorectal cancer who carry a normal, wild-type K-RAS gene.
planned subgroup analysis showed a significant survival benefit only in patients of Asian origin and in those who had never smoked. In June 2005, on the basis of the lack of a survival benefit in the ISEL study, the FDA restricted the use of gefitinib to patients participating in a clinical trial or continuing to benefit from treatment already initiated. Currently, gefitinib is marketed in several countries in eastern Asia but is not available in the United States or the European Union.
More recently, two randomized phase 3 trials evaluated the effectiveness of gefitinib monotherapy as compared with that of standard chemotherapy (docetaxel) as second-line treatment for chemotherapy-refractory non-small-cell lung cancer. The V-15-32 trial, conducted in Japan, failed to demonstrate the noninferiority of gefitinib in terms of overall survival, which was the primary end point. 34 However, in a large multicenter trial, this end point was achieved with gefitinib after platinum-based therapy had failed. 35 In addition, the side-effect profile appeared to favor gefitinib. 35 In a phase 2 study, the antitumor activity of erlotinib as a single agent in heavily pretreated non-small-cell lung cancer was similar to that of gefitinib. 36 More important, in the BR. 21 trial, a phase 3, randomized, double-blind, placebo-controlled study involving patients with pretreated non-small-cell lung cancer, erlotinib increased median survival by approximately 2 months as compared with placebo (Table 3) . 37 Responses were significantly more frequent in women, in patients with adenocarcinoma, and in patients with no history of smoking. However, a significant survival advantage was observed in all patient subgroups after treatment with erlotinib as compared with placebo. Quality-oflife analysis supported the palliative benefit of erlotinib in extending the time during which patients were free of symptoms (cough, dyspnea, and pain). 38 On the basis of these results, erlotinib was approved by the FDA in November 2004 and by the European Medicines Evaluation Agency (EMEA) in October 2005 for second-and third-line treatment of chemotherapy-resistant, advanced non-small-cell lung cancer. Several hypotheses have been proposed as to why the efficacy seems different for gefitinib and erlotinib in the similar BR.21 and ISEL phase 3 studies. One possible explanation is dosing: erlotinib was used at the maximum tolerated dose, whereas gefitinib was provided at a much lower dose. 39 On the basis of preclinical data demonstrating that anti-EGFR drugs potentiate the antitumor activity of cytotoxic drugs, four phase 3, double-blind, placebo-controlled, randomized clinical trials examined the combination of erlotinib or gefitinib with chemotherapy as first-line treatment for non-small-cell lung cancer. Two standard platinum-based, dual-drug regimens were used in combination with erlotinib or gefitinib. 40-43 Neither a survival advantage nor a benefit with respect to the response rate or time to progression was seen with the addition of gefitinib or erlotinib to chemotherapy in any of these trials. One possible reason that these trials failed to demonstrate any advantage of gefitinib or erlotinib is that they were conducted in Anti-EGFR monoclonal antibodies bind to the extracellular domain of EGFR and block ligand binding and receptor activation. Small-molecule EGFR tyrosine kinase inhibitors (TKIs) compete with ATP to bind to the intracellular EGFR tyrosine kinase catalytic domain and thus block EGFR autophosphorylation and downstream signaling. As a consequence of treatment with these drugs, key EGFR-dependent intracellular signals in cancer cells are affected. There is inhibition of cancer-cell proliferation (blockade of cell-cycle progression and G1 arrest through an increase in the p27 kip1 inhibitor of cyclin-dependent kinases); inhibition of tumor-induced angiogenesis by blockade of cancer-cell production of angiogenic factors, including transforming growth factor α, vascular endothelial growth factor, interleukin-8, and basic fibroblast growth factor; inhibition of cancer-cell invasion and metastasis; and potentiation of antitumor activity of cytotoxic drugs and radiotherapy. Cetuximab treatment is said to have relatively few side effects. The most common adverse events include skin toxicity (flushing, an acnelike rash, and folliculitis), fever and chills, asthenia, transient elevations in aminotransferase levels, and nausea. 45 Approximately 1.5% of patients have infusion reactions, which include allergic reactions requiring discontinuation of therapy; this rate is in keeping with the use of a chimeric human-mouse monoclonal antibody. Whereas cetuximab is marginally active as a single agent in advanced nonsmall-cell lung cancer, most phase 2 studies suggest that adding cetuximab to platinum-based therapies is of clinical benefit. 46-50 A large, multicenter, randomized, phase 3 study in which cetuximab was added to standard platinum-based chemotherapy (cisplatin and vinorelbine) has recently been completed (ClinicalTrials.gov number, NCT00148798). A more thorough evaluation of the role of cetuximab in the treatment of advanced non-small-cell lung cancer awaits publication of the results of this trial.
Colorectal Cancer
Cetuximab has been evaluated in both chemotherapy-refractory and untreated metastatic colorec- The mechanisms of action and pharmacologic effects of anti-EGFR monoclonal antibodies and small-molecule EGFR tyrosine kinase inhibitors do not completely overlap, and some of the differences between them may be clinically relevant (see Table 1 ). In particular, the anti-EGFR monoclonal antibody cetuximab, which is an IgG1 immunoglobulin, could elicit host antitumor immune responses, including antibody-dependent, cell mediated cytotoxicity (Panel A). Furthermore, anti-EGFR monoclonal antibodies can induce EGFR cellular internalization and down-regulation, thereby enhancing receptor degradation (Panel B). These two mechanisms could make an important contribution to antitumor activity. tal cancer. In phase 2 studies, cetuximab monotherapy was associated with response rates of 9 to 12%. Response rates of approximately 20% were achieved when cetuximab was used in combination with irinotecan in patients who had not had a response to previous therapy with irinotecan. 51-53 A multicenter, randomized, phase 2 trial evaluated the activity of cetuximab given alone or with irinotecan in patients who had not had a response to irinotecan monotherapy (Table 4) . 54 The cetuximab-irinotecan combination was significantly more effective than cetuximab monotherapy in terms of the response rate and rate of progression-free survival. However, the median survival was similar with the two approaches, mainly because of the crossover of patients from cetuximab monotherapy to the combination group on treatment failure. On the basis of these results, cetuximab was approved by the FDA in February 2004 for use in patients with metastatic colorectal cancer, either in combination with irinotecan (for patients who do not have a response to irinotecan alone) or as monotherapy (in patients who cannot tolerate irinotecan). The EMEA has approved cetuximab only in combination with irinotecan. A multicenter, randomized, phase 3 trial examined the combination of cetuximab plus irinotecan as second-line treatment for colorectal cancer in patients who had not had a response to an oxaliplatin-based regimen. Cetuximab plus irinotecan was significantly better than irinotecan alone in improving response rates, increasing progression-free survival, and improving the quality of life. 55 However, no differences were seen in overall survival, probably because almost half the patients crossed over to cetuximab treatment after the failure of irinotecan monotherapy. Recently, a randomized phase 3 trial comparing the use of cetuximab with best supportive care for patients in whom all available drugs, including fluoropyrimidines, oxaliplatin, and irinotecan, had failed showed that cetuximab increased progression-free survival, overall survival, and quality of life (Table 4) . 56 Cetuximab appears to be the only drug that does so with colorectal cancer who have had unsuccessful courses of all currently available chemotherapies.
Phase 2 studies 57,58 indicate that cetuximab combined with both irinotecan and oxaliplatinbased chemotherapies may have a role in the first-line treatment of metastatic colorectal cancer, with a 10 to 20% absolute increase in response rates reported. Such a response could be clinically relevant, particularly for the management of metastatic disease limited to the liver, since reductions in the number and size of metastases after administration of the drug might present the opportunity for potentially curative surgery. Recently, a multicenter, randomized, phase 3 study evaluated the combination of cetuximab with a standard chemotherapeutic regimen of fluorouracil, leucovorin, and irinotecan (FOLFIRI) in previously untreated metastatic colorectal cancer. Cetuximab plus FOLFIRI significantly increased response rates, prolonged progression-free survival, and increased the number of patients who could undergo potentially curative surgical removal of liver metastasis by a factor of approximately three. 59 Another monoclonal agent is panitumumab, a fully human anti-EGFR monoclonal antibody. 22 As seen with cetuximab, skin toxicity and diarrhea are the most common side effects of this agent. A randomized phase 3 clinical trial compared the use of panitumumab with the best supportive care in patients with colorectal cancer who had previously been treated unsuccessfully with a fluoropyrimidine, oxaliplatin, and irinotecan. A 10% response rate was reported, together with a significant reduction in the risk of tumor progression. 60 However, no difference was observed in overall survival, probably because of the preplanned crossover to panitumumab in the treatment group receiving the best supportive care. On the basis of these results, panitumumab was approved by the FDA in September 2006 as monotherapy for the treatment of metastatic colorectal cancer with disease progression after chemotherapy regimens consisting of a fluoropyrimidine, oxaliplatin, and irinotecan.
Squamous-Cell Carcinoma of the Head and Neck
The combination of cetuximab and radiotherapy was initially tested in patients with previously untreated, locally advanced squamous-cell carcinoma of the head and neck. In a randomized, multicenter, phase 3 clinical trial, patients were treated with radiotherapy alone or in combination with cetuximab (Table 5) . 61,62 Radiotherapy plus cetuximab significantly prolonged progression-free survival, duration of locoregional control, and overall survival. A randomized phase 3 trial of cisplatin plus cetuximab as compared with placebo in patients with previously untreated, metastatic squamous-cell carcinoma of the head and neck showed a significantly higher response rate in the group that received cisplatin plus cetuximab. 63 However, no significant difference in overall survival was observed, possibly because of the relatively small study sample. A recent larger, randomized, multicenter phase 3 trial showed that the addition of cetuximab to platinum-and fluorouracil-based chemotherapy in the first-line treatment of recurrent or metastatic squamous-cell carcinoma of the head and neck may be helpful, since progression-free survival and overall survival were significantly prolonged (Table 5) . 62 This phase 3 study is unique in showing a survival benefit for a novel treatment as compared with platinum-based chemotherapy in the treatment of this disease. Several phase 2 studies evaluated cetuximab alone or in combination with cisplatin in the treatment of platinum-resistant squamous-cell carcinoma of the head and neck, a cancer in which no specific therapy has been effective; such patients have a very short life expectancy. The overall response rate with cetuximab monotherapy was 10 to 13%, with a disease-control rate of ap- Median progression-free survival (mo) 
Pancreatic Cancer
A single-group phase 2 study suggested that cetuximab was promising when used in combination with gemcitabine for the treatment of advanced pancreatic cancer. 68 However, a more recent randomized phase 3 study failed to show a significant survival advantage with this combination as compared with standard treatment (gemcitabine monotherapy). 69 In contrast, another randomized phase 3 trial, which compared the combination of erlotinib (100 mg per day) and gemcitabine with gemcitabine alone, showed a significant improvement in response and survival rates (hazard ratio for death, 0.82; 95% confidence interval, 0.69 to 0.99; P = 0.04; 1-year survival rate, 23% vs. 17%, P = 0.02), and both the FDA and EMEA have approved this regimen for first-line treatment of pancreatic cancer. 70 Although the increase in survival could be considered modest in absolute terms, it showed that there is a significant advantage in adding an anticancer drug to gemcitabine in the treatment of metastatic pancreatic cancer -a unique finding.
Pr edic t ing the R e sp onse t o A nti-EGFR Drugs
Since only a subgroup of patients with cancer have a clinical benefit from treatment with EGFR inhibitors, there is an urgent need for identification and clinical validation of useful criteria for selecting patients for such treatment. A series of studies suggests that considering certain clinicopathological characteristics, as well as specific gene alterations, might help to identify patients whose cancers could be either sensitive or resistant to anti-EGFR therapy.
Clinical and Pathological Predictors
Most clinical studies of gefitinib or erlotinib in non-small-cell lung cancer suggest that Asian 
EGFR Protein Expression
EGFR expression as determined by immunohistochemical methods was the first biomarker investigated as a potential predictor of response. However, most studies have failed to show any relationship between EGFR expression and the clinical activity of anti-EGFR drugs. 24, 51 Cetuximab has also been shown to have clinical activity in patients with colorectal cancer that is negative for EGFR. 73 Similarly, in a prospective phase 2 clinical trial, the response to treatment with panitumumab in patients with metastatic colorectal cancer was similar whether EGFR protein expression was high, low, or negative, as assessed by immunohistochemical methods. 74 Collectively, these data suggest that immunohistochemical testing for EGFR is not an optimal method for identifying patients who may have a response to treatment with anti-EGFR drugs.
Somatic EGFR Gene Mutations
The discovery that certain somatic mutations within the tyrosine kinase, ATP-binding domain of the EGFR gene are associated with a response to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer suggested that the selection of patients through molecular screening might be feasible. The association between EGFR mutations and a response to erlotinib or gefitinib has been retrospectively confirmed in several clinical studies. 6 It has been also suggested that this association translates into improved survival. 6 However, in larger randomized studies, such as the BR.21 trial, a similar survival advantage was observed for patients treated with erlotinib, independently of the presence of EGFR mutations or of a wild-type EGFR gene, indicating that the presence of EGFR mutations is not the only biomarker for predicting a survival benefit of treatment with small-molecule EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer. 83
Increased EGFR Copy Number
The EGFR gene is rarely amplified in human cancers. However, fluorescence in situ hybridization (FISH) shows an increased EGFR copy number with balanced polysomy in a high proportion of cancer cells in approximately 25 to 40% of patients with non-small-cell lung cancer, squamous-cell carcinoma of the head and neck, or colorectal cancer. A single-group, phase 2 trial of The predictive role of increased EGFR copy numbers has also been evaluated in patients with metastatic colorectal cancer in a series of retrospective studies. The first report on the correlation between positive results for EGFR and a response to therapy with cetuximab or panitumumab involved a small cohort of patients (31 patients) with advanced, chemotherapy-refractory colorectal cancer. 86 Recently, a FISH analysis of EGFR in tumor samples from patients enrolled in the phase 3 study comparing the use of panitumumab with best supportive care was reported. 87 In the group treated with panitumumab, patients with normal EGFR copy numbers had a shorter median progression-free survival and overall survival than patients with high EGFR copy numbers. Moreover, in the group treated only with best supportive care, no correlation between EGFR copy numbers and survival was observed, suggesting a predictive rather than a prognostic role of this genetic feature in patients with metastatic colorectal cancer who are treated with anti-EGFR monoclonal antibodies.
R esis ta nce t o EGFR A ntag onis ts

Intrinsic Resistance
Activating mutations in the K-RAS gene, which result in EGFR-independent activation of the mitogen-activated protein kinase pathway, are found in approximately 15 to 30% of patients with nonsmall-cell lung cancer and 40 to 45% of patients with colorectal cancer, and their presence generally correlates with a worse prognosis with respect to the outcome of the cancer. K-RAS mutations occur in patients with a history of substantial cigarette use. 88,89 These mutations are most frequently recorded in codons 12 and 13 in the exon 2 of the K-RAS gene and are generally mutually exclusive with EGFR mutations. In several studies, K-RAS mutations have been significantly associated with lack of response to EFGR tyrosine kinase inhibitors in patients with non-small-cell lung cancer and with lack of response to cetuximab or to panitumumab in patients with advanced, chemotherapy-refractory colorectal cancer. Both findings suggest that EGFR-independent, constitutive activation of the K-RAS signaling pathway could impair the response to anti-EGFR drugs. 90-98 However, no correlation between K-RAS mutations and efficacy was reported in the INTEREST trial, which compared docetaxel and gefitinib as second-line treatments for nonsmall-cell lung cancer. 35 In contrast, the results of the phase 3 trial comparing the use of panitumumab with best supportive care in chemotherapy-refractory colorectal cancer have confirmed that the efficacy of panitumumab is limited to patients whose tumors carry the wildtype K-RAS gene. 99
Acquired Resistance
In patients with non-small-cell lung cancer that initially responds to gefitinib or erlotinib, an acquired resistance to EGFR inhibitors, resulting in treatment failure, is associated with the development of an additional EGFR mutation. 6 The most extensively studied of such EGFR mutations occurs in exon 20, resulting in a substitution of methionine for threonine in codon 790 (T790M). [100] [101] [102] This mutation causes a change in the tridimensional structure of the tyrosine kinase domain and prevents both erlotinib and gefitinib from binding to EGFR. 103 According to a recent report, amplifi- 
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INTRODUCTION
The American Society of Clinical Oncology (ASCO) has established a rigorous, evidence-based approach-the provisional clinical opinion (PCO)-to offer a rapid response to emerging data in clinical oncology. The PCO is intended to offer timely clinical direction to ASCO's oncologists following publication or presentation of potentially practice-changing data from major studies (Appendix). This PCO addresses only the utility of testing for mutations in codons 12 or 13 of the KRAS gene in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (MoAb) therapy, that is, cetuximab or panitumumab.
STATEMENT OF THE CLINICAL ISSUE
Results from phase II and III clinical trials of the anti-EGFR MoAbs cetuximab and panitumumab when used either as monotherapy or in combination with chemotherapy, have shown that patients with metastatic colorectal carcinoma may benefit from these therapies and both agents are approved by the US Food and Drug Administration (FDA) for treatment of metastatic colorectal cancer. Stratified analyses of data from these trials by KRAS mutational status-not detected ("wild type") or abnormal (mutated)-indicated that patients with KRAS mutation in codon 12 or 13 did not derive benefit from treatment with cetuximab or panitumumab.
ASCO'S PROVISIONAL CLINICAL OPINION
Based on a systematic review of the relevant literature, all patients with metastatic colorectal carcinoma who are candidates for anti-EGFR monoclonal antibody therapy should have their tumor tested for KRAS mutations in a CLIA-accredited laboratory. If KRAS mutation in codon 12 or 13 is detected, then patients with metastatic colorectal carcinoma should not receive anti-EGFR monoclonal antibody therapy as part of their treatment.
LITERATURE REVIEW AND ANALYSIS
The review of the evidence on which this PCO is based consists primarily of the rigorous systematic review of the literature conducted by the Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center (TEC). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Details of the BCBSA TEC assessment can be found in the full TEC report, which is available at www .bcbs.com/blueresources/tec/press/KRAS-mutations-epidermal.html. In summary, the TEC searched MEDLINE through October 2008 to identify all relevant articles on anti-EGFR MoAb therapy and KRAS mutation analysis. The TEC supplemented its review by searching for relevant abstracts from the ASCO 2008 Annual Meeting via the online database (www.asco.org/vm). Studies were included in the TEC assessment if they were peer-reviewed, fulllength, English-language articles and investigated response to anti-EGFR MoAbs among patients with metastatic colorectal cancer with respect to KRAS mutational status. The TEC also included phase II and III randomized clinical trials from the 2008 ASCO Annual Meeting if the full presentation slides were available online.
The TEC review identified post hoc analyses on subsets from five randomized, controlled trials (RCTs) of cetuximab or panitumumab that evaluated outcomes for patients with metastatic colorectal cancer in relation to KRAS mutational status (Table 1) ; and five single-arm studies that retrospectively evaluated treatment response according to KRAS status (Table 2) . Two broad findings emerged from the TEC assessment of these studies: (1) a consistent correlation between presence of a KRAS mutation in codon 12 or 13 and lack of response to anti-EGFR MoAb therapy in patients with metastatic colorectal cancer; and (2) evidence of improved tumor response, progression-free, and/or overall survival in response to anti-EGFR MoAb therapy only in those patients with no mutation in codon 12 or 13 (wild type) versus abnormal (mutated) KRAS tumors in analyses from four of five RCTs.
Oncologists should understand that both the PCO and the TEC review are based on assays that detect mutations in codons 12 and 13 of KRAS only. Mutations also occur, although uncommonly, at codons 61 and 146, and these also activate KRAS. In addition, the PCO and the TEC review do not evaluate the differences in sensitivity and specificity among the various assays that are available for KRAS mutation testing 18 and expression of epiregulin or amphiregulin 7 that may indicate response). These subjects are either the focus of current research, or there are insufficient data to justify an opinion at present.
• Freshly extracted from patient, provided fresh or in RNA preservation solution such as RNAlater • Freshly extracted from patient and rapidly frozen and stored frozen • Neutral buffered formalin fixed and paraffin embedded, area of interest selected specifically by the pathologist Acceptable assay types. In all cases, DNA is first extracted by laboratory specific and standardized protocols that incorporate standards to assure adequate and specific extraction.
• Real-time polymerase chain reaction. In real-time polymerase chain reaction, fluorescent probes specific for the most common mutations in codons 12 and 13 are utilized. Abbreviations: EGFR, epidermal growth factor receptor; CRC, colorectal cancer; WT, wild type; PFS, progression-free survival; OS, overall survival. 
Background
Fluoropyrimidine-based chemotherapy plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic colorectal cancer. We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer.
Methods
We randomly assigned 755 patients with previously untreated metastatic colorectal cancer to capecitabine, oxaliplatin, and bevacizumab (CB regimen, 378 patients) or the same regimen plus weekly cetuximab (CBC regimen, 377 patients). The primary end point was progression-free survival. The mutation status of the KRAS gene was evaluated as a predictor of outcome.
Results
The median progression-free survival was 10.7 months in the CB group and 9.4 in the CBC group (P = 0.01). Quality-of-life scores were lower in the CBC group. The overall survival and response rates did not differ significantly in the two groups. Treated patients in the CBC group had more grade 3 or 4 adverse events, which were attributed to cetuximab-related adverse cutaneous effects. Patients treated with cetuximab who had tumors bearing a mutated KRAS gene had significantly decreased progression-free survival as compared with cetuximab-treated patients with wildtype-KRAS tumors or patients with mutated-KRAS tumors in the CB group.
Conclusions
The addition of cetuximab to capecitabine, oxaliplatin, and bevacizumab resulted in significantly shorter progression-free survival and inferior quality of life. Mutation status of the KRAS gene was a predictor of outcome in the cetuximab group. 
564
F luoropyrimidines (e.g., fluorouracil and capecitabine), irinotecan, and oxaliplatin are the standard cytotoxic drugs used in treating metastatic colorectal cancer. 1,2 The combination of capecitabine and oxaliplatin is similar to the combination of fluorouracil and oxaliplatin in efficacy and safety. 3, 4 Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), 5-7 combined with fluoropyrimidine-based chemotherapy is now the standard first-line treatment for metastatic co lo rec tal cancer. Cetuximab, a chimeric IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR), has efficacy as monotherapy and in combination with irinotecan in irinotecan-resistant patients. 8, 9 We prospectively evaluated the addition of cetuximab to capecitabine, oxaliplatin, and bevacizumab as first-line treatment in patients with metastatic colorectal cancer (the CAIRO2 trial).
Me thods
Patients
Eligible patients were older than 18 years of age, had histologically proved colon or rectal carcinoma, metastatic disease not amenable to curative surgery, measurable tumor, no previous systemic chemotherapy for metastatic disease, World Health Organization (WHO) performance status 0 or 1, no adjuvant chemotherapy within 6 months before randomization, and adequate bone marrow, liver, and renal function. We excluded patients if they had higher than grade 1 sensory neuropathy, previous intolerance of adjuvant chemotherapy, symptomatic central nervous system metastases, bleeding diathesis, coagulation disorders, clinically significant cardiovascular disease, or other cancers within the previous 5 years, except for adequately treated squamous or basalcell carcinoma of the skin or carcinoma in situ of the cervix.
Study design
This open-label, randomized, phase 3 trial was conducted in 79 centers in the Netherlands. Eligible patients were randomly assigned at a 1:1 ratio to receive treatment with or without cetuximab. Randomization was performed centrally by a minimization technique with stratification according to serum lactate dehydrogenase level (normal or abnormal, according to the cutoff values of each individual center), previous adjuvant chemotherapy (yes or no), number of affected organs (one or more than one), and treatment center. The study was approved by the Committee on Human-Related Research Arnhem-Nijmegen and by the local institutional review boards. An independent data and safety monitoring committee evaluated all serious adverse events. All patients provided written informed consent before study entry.
Bevacizumab was donated by Roche, and cetuximab was donated by Merck Serono. The sponsors of the study were informed of the results of the study but did not contribute to any phase of the study design; the collection, analysis, and interpretation of the data; or the writing of the manuscript.
Treatment and Testing
Treatment for the capecitabine-bevacizumab (CB) group consisted of 1000 mg of capecitabine per square meter of body-surface area, given orally twice daily on days 1 to 14; 130 mg of oxaliplatin per square meter, given intravenously on day 1; and 7.5 mg of bevacizumab per kilogram of body weight, given intravenously on day 1. Treatment for the capecitabine-bevacizumab-cetuximab (CBC) group consisted of the same regimen of capecitabine, oxaliplatin, and bevacizumab plus 400 mg of cetuximab per square meter, given intravenously on day 1 of the first treatment cycle, followed by 250 mg of cetuximab per square meter given weekly thereafter. All treatment cycles were administered every 3 weeks. In both treatment groups, oxaliplatin was administered for a maximum of six cycles to prevent serious peripheral sensory neurotoxicity, and from cycle 7 the dose of capecitabine was increased to 1250 mg per square meter.
Adverse effects were graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0. Dose reductions because of adverse events were performed for each agent as specified in the study protocol. A cetuximab-related adverse cutaneous effect was defined as any adverse cutaneous effect with the exception of handfoot syndrome. Central review was performed of the charts of all patients who died within 30 days after the last administration of the study drugs and whose death was accompanied by any event other than disease progression, regardless of the reported cause. The results of the central review were submitted to the independent data and safety monitoring committee for final assessment. An interim analysis of safety in the first 400 patients has been published. 10 Tumor response was assessed by the local investigators every 9 weeks with the use of computed tomographic scans, according to the Response Evaluation Criteria in Solid Tumors (RECIST). 11 The overall response rate was defined as the rate of all responses, including complete and partial responses. Disease control was defined as complete response, partial response, or stable disease as the best response. Treatment was continued until the occurrence of disease progression, death, or unacceptable adverse event, whichever came first. Patients whose treatment was discontinued for reasons other than disease progression were evaluated for a response every 3 months. The relative dose intensity was defined as the ratio of the dose administered to the planned dose. Quality of life was assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire at baseline within 2 weeks before randomization and every 9 weeks thereafter until the end of the study treatment.
Formalin-fixed, paraffin-embedded tumor material was collected from patients for whom resected primary tumor tissue was available. DNA was extracted from tumor tissue for mutation analysis of the KRAS gene (see the Supplementary Appendix, available with the full text of this article at NEJM.org).
EGFR expression was determined by immunohistochemical assay on tissue microarrays with the use of the EGFR pharmDx Kit (Dako) according to the manufacturer's instructions. Powervision (Immunologic) was used as a visualization method. In accordance with the pharmDx Kit guidelines, tumors showing more than 1% membranous EGFR stained cells were considered positive.
Statistical Analysis
The primary end point was progression-free survival, which was defined as the interval from the date of randomization to the date of disease progression, death, or last follow-up, whichever occurred first. It was estimated that with 540 events (progression or death), a two-sided log-rank test at a significance level of 5% would have a power of 80% to detect a difference in median progression-free survival of 11 to 14 months (hazard ratio, 0.79). On the assumption of an accrual and followup period of 36 months, we planned to include approximately 750 patients in the study. The secondary end points were overall survival, safety, response rate, quality of life, and the influence of KRAS mutational status and expression of EGFR in tumor samples on the outcome. Ineligible patients or patients who withdrew informed consent were excluded from all analyses. Data from eligible patients were analyzed according to the intention-to-treat principle, and these patients remained in follow-up until disease progression occurred. Data from patients who were alive without recurrence at the time of analysis were censored. The progression-free and overall survival curves were estimated by the Kaplan-Meier method and compared by means of the log-rank test. We performed a multivariate analysis using a Cox proportional-hazards model with treatment group, serum lactate dehydrogenase level, number of affected organs, and previous adjuvant chemotherapy as covariables.
Patients who started treatment were evaluated for adverse events, and patients who completed at least three cycles were evaluated for response. The worst grade of adverse event was compared between the treatment groups with the use of the chi-square test. The correlation between cetuximab-related adverse cutaneous effects and survival was assessed in a landmark-type analysis. Patients who started treatment were grouped according to the worst grade of cetuximab-related adverse cutaneous effect reported during the first six cycles. The Wilcoxon rank-sum test was used to detect statistically significant differences between the treatment groups in the change in the mean quality-of-life score. Patients who completed the quality-of-life questionnaire at baseline and at least once during treatment were evaluated. All analyses were performed with the use of SAS software, version 9.1. group) were well matched between the two groups except for sex ( (15 and 7) ; cetuximab was usually administered in combination with irinotecan.
R esults
Efficacy
The primary end point was reached in 293 patients in the CB group and 316 patients in the CBC group. The addition of cetuximab significantly decreased the median progression-free survival (10.7 months in the CB group and 9.4 months in the CBC group, P=0.01) ( Table 2 and Fig. 1A ). The hazard ratio for disease progression or death in the CBC group was 1.22 (95% confidence interval, 1.04 to 1.43). In a multivariate analysis, an elevated serum lactate dehydrogenase level (P<0.001) and treatment group (P = 0.03) correlated significantly with progression-free survival. The median overall survival was 20.3 months in the CB group and 19.4 months in the CBC group (P = 0.16) ( Table 2 and Fig. 1B) . A total of 407 patients died, 193 in the CB group and 214 in the CBC group. The rate of death from any cause at 60 days was 1.9% in the CB group and 2.7% in the CBC group. The overall response rate in the 649 patients who were evaluated was 50.0% in the CB group and 52.7% in the CBC group (P = 0.49). Disease control was observed in 94.0% of the patients in the CB group and 94.6% of those in the CBC group (P = 0.72).
Subgroup Analyses
The mutation status of the KRAS gene was evaluated in 528 tumors ( 568 mors (45.9% vs. 61.4%, P = 0.03), whereas no significant difference was observed in the CB group (59.2% vs. 50.0%, P = 0.16). EGFR was evaluated in 496 tumors, of which 315 (63.5%) tested positive. The baseline characteristics were not significantly different between EGFR-positive and EGFR-negative patients (data not shown). Among EGFR-positive patients, the median progression-free survival was 12.2 months in the CB group and 9.8 months in the CBC group (P = 0.003). We did not observe a significant correlation between KRAS mutation status or EGFR expression and the incidence of cetuximab-related adverse cutaneous effects (data not shown).
As compared with women in the CBC group, women who were assigned to the CB group had significantly better progression-free survival (12.5 vs. 8.6 months, P<0.001) and overall survival (20.1 vs. 18.8 months, P = 0.02). However, these differences were not observed in men. The distribution of baseline characteristics was similar in women and men. In a multivariate analysis, the interaction between sex and treatment group was statistically significant for progression-free survival (P = 0.005) but not for overall survival (P = 0.10).
The severity of cetuximab-related adverse cutaneous effects correlated significantly with progression-free survival (P<0.001) (Fig. 2B) . The median progression-free survival in patients with grade 0 or 1, patients with grade 2, and patients with grade 3 cetuximab-related adverse cutaneous effects was 7.8 months, 10.2 months, and 11.4 months, respectively. The progression-free survival did not differ significantly between patients in the CB group and patients with grade 3 cetuximabrelated adverse cutaneous effects in the CBC group (P = 0.72). Table 4 and the Supplementary Appendix list the most frequently observed grade 3 or 4 adverse events. The incidence of any grade 3 or 4 adverse event was 73.2% in the CB group and 81.7% in the CBC group (P = 0.006). When grade 3 cetuximabrelated adverse cutaneous effects were excluded from this analysis, the incidence was similar: 73.2% in the CB group and 74.3% in the CBC group (P = 0.74).
Safety
Quality of Life
A total of 532 patients (276 in the CB group and 256 in the CBC group) were evaluated for quality of life. Overall quality of life and global health status were similar in the two groups at baseline; during treatment, both measures improved significantly more in the CB group than in the CBC group (P = 0.007 and P = 0.03, respectively). The mean increase in global health status was 0.4 
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point in the CB group and 0.0 points in the CBC group (P = 0.007). There were no significant differences between the treatment groups in the change from baseline in scores for pain, financial problems, and decrease in functioning (physical, emotional, cognitive, and social).
Discussion
In this randomized trial conducted in previously untreated patients with metastatic colorectal cancer, the addition of cetuximab to treatment with capecitabine, oxaliplatin, and bevacizumab resulted in a significant decrease in progressionfree survival and a poorer quality of life. The reduction in progression-free survival was unexpected, since preclinical as well as early clinical studies suggested a benefit from the combination of anti-VEGF and anti-EGFR antibodies. [12] [13] [14] [15] An increase in adverse events is an unlikely cause of the reduction in progression-free survival, since such events were manageable and the percentage of patients who discontinued treatment because of adverse events was similar in the two treatment groups. A similar result with anti-EGFR therapy was observed in the Panitumumab Advanced Colo rectal Cancer Evaluation (PACCE) trial, 16, 17 in which previously untreated patients with metastatic colorectal cancer were randomly assigned to fluorouracil, leucovorin, bevacizumab, and irinotecan or oxaliplatin, with or without panitumumab, a human antibody against EGFR. The PACCE trial was prematurely discontinued because of decreased progression-free survival and increased adverse events in the panitumumab group, but the decrease in progression-free survival was observed only in patients who were treated with oxaliplatin. The Bowel Oncology with Cetuximab Antibody (BOND) 2 trial showed efficacy in treatment with irinotecan, bevacizumab, and cetuximab in patients with irinotecan-resistant colorectal cancer, 18 a result that suggested a higher response rate and longer progression-free survival than was found in a previous trial (BOND) of irinotecan and cetuximab in similar patients. 9 Preliminary results of chemotherapy with or without cetuximab in the first-line treatment of metastatic colorectal cancer indicate somewhat better progression-free survival with irinotecan than with oxaliplatin, 19, 20 but these comparisons should be interpreted with caution: whether cetuximab is more efficacious when given in combination with irinotecan than with oxaliplatin remains speculative.
The results of our trial might be due to a negative interaction between cetuximab and bevacizumab. Hypertension, a common side effect of bevacizumab treatment, was recently shown to correlate with clinical outcome in patients with colorectal cancer. 21 Our observation that hypertension was less frequent in the CBC group suggests decreased efficacy of bevacizumab when administered in combination with cetuximab. In contrast, preclinical studies have suggested a positive interaction between VEGF-and EGFRinhibiting agents. [12] [13] [14] [15] However, to our knowledge, the combination of cetuximab and bevacizumab has not been tested in this setting.
The severity of cetuximab-related adverse cutaneous effects correlated directly and significantly with progression-free survival, but the median progression-free survival among patients with the most severe cetuximab-related adverse cutaneous effects was not significantly better than that among patients treated without cetuximab.
Women treated with cetuximab had shorter progression-free survival than women treated Among patients in the group receiving capecitabine, oxaliplatin, and bevacizumab plus cetuximab (CBC), the median progression-free survival was significantly decreased when their tumor harbored a KRAS mutation (8.1 vs. 10.5 months, P = 0.04) (Panel A). Among patients with mutated-KRAS tumors, the median progression-free survival was significantly decreased in the CBC group as compared with the group receiving capecitabine, oxaliplatin, and bevacizumab (CB) (8.1 vs. 12.5 months, P = 0.003). In the CBC group, the median progression-free survival in treated patients with grade 0 or 1, treated patients with grade 2, and treated patients with grade 3 cetuximab-related adverse cutaneous effects was 7.8 months, 10.2 months, and 11.4 months, respectively (P<0.001) (Panel B). The difference between patients with grade 3 adverse cutaneous effects in the CBC group and patients in the CB group was not statistically significant (P=0.72).
The without cetuximab, but this difference was not found in men. Women also had a lower incidence of grade 3 cetuximab-related adverse cutaneous effects, which might indicate a decreased efficacy of cetuximab in our study. Although the management of adverse cutaneous effects may be different in women than in men, with earlier discontinuation of cetuximab in women for cosmetic reasons, this would not explain the poorer results in the CBC group. The KRAS genotype affects the response to anti-EGFR treatment: patients with wild-type-KRAS tumors have longer progression-free survival than those with mutated-KRAS tumors. [22] [23] [24] [25] [26] The results of our study also confirm the role of the mutation status of the KRAS gene in the response to cetuximab when cetuximab is administered in combination with chemotherapy and bevacizumab as first-line treatment. We observed the worst result for progression-free survival in patients with mutated-KRAS tumors who were treated with cetuximab. A similar result was found in trials of chemotherapy with or without cetuximab as first-line treatment of metastatic colorectal cancer. 25, 26 Many targeted agents are available or under development for use in a wide range of tumors. The inhibition of a single signal-transduction pathway is unlikely to provide optimal results, and therefore a combination of agents appears to be a valid strategy. Our results, however, argue against the combined use of anti-VEGF and anti-EGFR monoclonal antibodies with chemotherapy in cases of metastatic colorectal cancer. We thank Marjolijn J.L. Ligtenberg, Ph.D., for the interpretation of the KRAS data and Annelies Klaasen, B.Sc., for laboratory assistance. 
